 |
|
|
| |
Safety, Pharmacokinetics and Antiviral Activity of Novel
HBV Capsid Assembly Modulator, JNJ-56136379, in
Non-cirrhotic, Treatment-naïve Patients with Chronic
Hepatitis B
|
| |
| |
Reported by Jules Levin
APASL 2018 March 14-18 Aerocity, New Delhi
M. Buti,1 F. Zoulim,2,3 J.Z. Yogaratnam,4 J.J. Vandenbossche,5 O. Lenz,5 W. Talloen,5 C. Vistuer,5
I. Moscalu,6 A. Streinu-Cercel,7 S. Bourgeois,8 J. Crespo,9 J.M. Pascasio,10 L. Blatt,4 J. Fry4
1Hospital Universitario Vall d'Hebron, Unidad de Heptologia, Barcelona, Spain; 2Department of Hepatology, Croix
Rousse Hospital, Hospices Civils de Lyon, Lyon, France; 3INSERM U1052-Cancer Research Institute of Lyon, Lyon,
France; 4Alios Biopharma, South San Francisco, CA, USA; 5Janssen Pharmaceuticals, Beerse, Belgium; 6Spitalul Clinic
Republican, Chisinau, Moldavia; 7Carol Davila University of Medicine and Pharmacy, National Institute for Infectious
Diseases "Prof.Dr. Matei Bals", Bucharest, Romania; 8ZNA Jan Palifjn, Clinical Pharmacology Unit, Merksem, Belgium,
9Hospital Universitario Marques de Valdecilla, Unidad de Ensayos Clinicos, Santander, Spain; 10Hosiptal Universitario
Virgen del Rocio, UGC Enfermedades Digestivas, Sevilla, Spain
|
| |
|
|
|
|
|
